Development and licensing agreement for RON (Recepteur d’Origine Nantais) receptorDevelopment and Licensing Agreement • January 29th, 2022
Contract Type FiledJanuary 29th, 2022n/d : Centocor Ortho Biotech will also fund certain research conducted by AVEO, including translational research studies using its Human Response Platform to identify biomarkers for patients most likely to benefit from treatment with RON-targeted antibodies